Treatments for SARS-CoV-2 infection : A retrospective study of drug-drug interactions and safety
Copyright © 2021 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved..
OBJECTIVES: The aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave.
METHODS: We retrospectively analyzed patients treated by drugs used in SARS-CoV-2 infection (Azithromycin, Hydroxychloroquine and/or Lopinavir/ritonavir) between 15th March 2020 to 17th April 2020. A review of adverse events and DDI-risky drug association on medical record was conducted for each patient. Each adverse events was analyzed by the Centre régional de pharmacovigilance (CRPV) to assess causality of drugs used in SARS-CoV-2 infection.
RESULTS: A total of 312 precriptions were analyzed during the period, of which 110 prescriptions had 157 drug association at risk of DDIs; 26 adverse events were reported. Causality assessment by CRPV concluded that 10 (35,7 %) adverse effects were possibly related to SARS-CoV-2 drugs with only 2 (7,1 %) related to DDIs.
CONCLUSIONS: Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Annales pharmaceutiques francaises - 80(2022), 4 vom: 07. Juli, Seite 531-542 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Médicaments utilisés dans la prise en charge de l’infection à SARS-CoV-2 : étude rétrospective des principales associations à risque d’interactions médicamenteuses et des effets indésirables médicamenteux |
|---|
| Beteiligte Personen: |
Dubois, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.06.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharma.2021.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332867706 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332867706 | ||
| 003 | DE-627 | ||
| 005 | 20231225220448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.pharma.2021.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332867706 | ||
| 035 | |a (NLM)34748737 | ||
| 035 | |a (PII)S0003-4509(21)00160-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Dubois, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatments for SARS-CoV-2 infection |b A retrospective study of drug-drug interactions and safety |
| 246 | 3 | 3 | |a Médicaments utilisés dans la prise en charge de l’infection à SARS-CoV-2 : étude rétrospective des principales associations à risque d’interactions médicamenteuses et des effets indésirables médicamenteux |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVES: The aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave | ||
| 520 | |a METHODS: We retrospectively analyzed patients treated by drugs used in SARS-CoV-2 infection (Azithromycin, Hydroxychloroquine and/or Lopinavir/ritonavir) between 15th March 2020 to 17th April 2020. A review of adverse events and DDI-risky drug association on medical record was conducted for each patient. Each adverse events was analyzed by the Centre régional de pharmacovigilance (CRPV) to assess causality of drugs used in SARS-CoV-2 infection | ||
| 520 | |a RESULTS: A total of 312 precriptions were analyzed during the period, of which 110 prescriptions had 157 drug association at risk of DDIs; 26 adverse events were reported. Causality assessment by CRPV concluded that 10 (35,7 %) adverse effects were possibly related to SARS-CoV-2 drugs with only 2 (7,1 %) related to DDIs | ||
| 520 | |a CONCLUSIONS: Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse drug reaction | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Drug-drug interaction | |
| 650 | 4 | |a Effets secondaires et réactions indésirables d’origine médicamenteuse | |
| 650 | 4 | |a Incompatibilité entre médicaments | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Féral, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pain, J-B |e verfasserin |4 aut | |
| 700 | 1 | |a Michot, J |e verfasserin |4 aut | |
| 700 | 1 | |a Fansi Ndengoue, D |e verfasserin |4 aut | |
| 700 | 1 | |a Benomar, A |e verfasserin |4 aut | |
| 700 | 1 | |a Clou, E |e verfasserin |4 aut | |
| 700 | 1 | |a Debrix, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales pharmaceutiques francaises |d 1945 |g 80(2022), 4 vom: 07. Juli, Seite 531-542 |w (DE-627)NLM000046493 |x 0003-4509 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2022 |g number:4 |g day:07 |g month:07 |g pages:531-542 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharma.2021.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2022 |e 4 |b 07 |c 07 |h 531-542 | ||